Skip to content

Released May 13, 2026, before the open

10-Q filed May 13, 2026, 43 days after period end · 0001193125-26-220696

Q1 2026 · 10-Q
Revenue$1.30M−20.3% vs Q1 2025−5.1% vs Q4 2025
Net Income-$31.21MN/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.26N/M vs Q1 2025no prior Q4 2025 on file
Operating Income-$33,000,000N/M
Operating Cash Flow-$30,822,000N/M
Free Cash Flowderived-$31,061,000N/M
Margins · derived
Operating margin-2540.4%−6.3 pt vs Q1 2025
Net margin-2402.8%−93.4 pt vs Q1 2025

What the release said

The release

Same quarter

MetricQ1 2026Q1 2025Q1 2024Q1 2023
Revenue$1.30M$1.63M$1.93M$58.98M
Net Income-$31.21M-$37.62M-$48.00M-$18.88M
EPS Diluted-$0.26-$0.32-$0.47-$0.19

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR